Abstracting and Indexing

  • Google Scholar
  • CrossRef
  • WorldCat
  • ResearchGate
  • Academic Keys
  • DRJI
  • Microsoft Academic
  • Academia.edu
  • OpenAIRE

The Relationship between High Absolute Lymphocyte Counts and Favorable Prognosis in Eribulin Therapy is seen in First-Line Chemotherapy for Metastatic Breast Cancer: Combined Analysis of Two Phase 2 Studies

Author(s): Kosei Kimura, Tsutomu Takashima, Hiroyo Oku, Ayana Ikari, Tomo Tominaga, Saki Takai, Junna Sakane, Michiaki Tanaka, Hidemi Kawajiri, Shinichiro Kashiwagi, Shinya Tokunaga, Shigehiko Nishimura, Satoru Noda, Mitsuhiko Iwamoto

Background: While absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) are associated with prolonged progression-free survival (PFS) and overall survival (OS), the influence of previous chemotherapy on blood cell counts may necessitate an evaluation of baseline ALC and NLR in first-line chemotherapy patients.

Methods: Patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who received first-line eribulin chemotherapy in two phase 2 trials (BIRICHEN and OMC-BC 03) were retrospectively analyzed. HER2-negative MBC patients who received first-line chemotherapy other than eribulin (treatment of physician’s choice; TPC) at Osaka Medical and Pharmaceutical University Hospital between March 2013 and March 2017 were also analyzed for comparison.

Results: In the eribulin group, the median OS (mOS) was 30.9 and 17.8 months in the high-(H-)ALC (≥1500/μL; n = 33) and low-(L-)ALC (<1500/μL; n = 26) groups, respectively (hazard ratio [HR], 0.52; 95% confidence interval [CI]: 0.27–1.01), whereas it was 30.9 and 15.4 months in the L-NLR (<2.5; n = 23) and H-NLR (≥2.5; n = 36) groups, respectively (HR, 0.49; 95% CI: 0.25–0.95). In the TPC group, neither ALC nor NLR was associated with OS or PFS extension. After propensity-score matching, the mOS in the eribulin group was 32.0 and 19.6 months in the H-ALC and L-ALC groups, respectively (HR, 0.43; 95% CI: 0.18–0.99), while the mOS in the L-NLR and H-NLR groups showed no significant differences in the eribulin group (HR, 0.65; 95% CI: 0.27–1.58).

Conclusions: ALC is a prognostic marker for first-line eribulin chemotherapy, but not for other agents.

Grant Support Articles

© 2016-2022, Copyrights Fortune Journals. All Rights Reserved!